이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)

2026년 10월 22일 업데이트: GlaxoSmithKline

A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) Versus Imatinib in Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)

Gastrointestinal Stromal Tumour (GIST) is a soft tissue tumour that develops in the digestive system, most often in the stomach or small intestine. It is caused by changes in certain proteins that cause the cells to grow uncontrollably. Although current treatments may be effective, tumours may stop responding over time, highlighting the need for newer options. This study is evaluating velzatinib (GSK6042981) in participants with newly diagnosed GIST that has spread or cannot be surgically removed. Velzatinib will be compared with imatinib, the standard treatment, to assess whether it can delay disease worsening and is safe and well tolerated.

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

800

단계

  • 3단계

확장된 액세스

사용 가능 임상시험 외. 확장 액세스 기록을 참조하세요.

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

      • Thessaloniki, 그리스, 54639
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Grigorios Rallis
      • Thessaloniki, 그리스, 55535
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Ioannis Boukovinas
    • Attica
      • Chaïdári, Attica, 그리스, 124 62
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Anastasios Kyriazoglou
    • Crete
      • Heraklion, Crete, 그리스, 700 13
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Ioannis Souglakos
      • Nijmegen, 네덜란드, 6525GA
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Ingrid Desar
    • South Holland
      • Leiden, South Holland, 네덜란드, 2333 ZA
        • 모병
        • GSK Investigational Site
        • 수석 연구원:
          • Hans Gelderblom
        • 연락하다:
        • 연락하다:
      • Oslo, 노르웨이, 0379
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Kjetil Boye
      • Changhua, 대만, 500
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Ruo-Han TSENG
      • Taichung, 대만, 404
        • 모병
        • GSK Investigational Site
        • 수석 연구원:
          • Li-Yuan Bai
        • 연락하다:
        • 연락하다:
      • Taipei, 대만, 10002
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Kun-Huei Yeh
      • Taipei, 대만, 112
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Chueh-Chuan Yen
      • Taoyuan, 대만, 33305
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Chun-Nan Yeh
      • Seongnam-si Gyeonggi-do, 대한민국, 13620
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Ji-Won Kim
      • Seoul, 대한민국, 03080
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Do-youn Oh
      • Seoul, 대한민국, 03722
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Minkyu Jung
      • Seoul, 대한민국, 138-736
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Min-Hee Ryu
      • Seoul, 대한민국, 03181
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Dong-Hoe Koo
      • Suwon Kyunggi-do, 대한민국, 16499
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Tae Hwan Kim
    • Seoul Teugbyeolsi
      • Seoul, Seoul Teugbyeolsi, 대한민국, 06351
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Jungyong Hong
    • Arizona
      • Scottsdale, Arizona, 미국, 85258
        • 모병
        • GSK Investigational Site
        • 수석 연구원:
          • Michael Gordon
        • 연락하다:
        • 연락하다:
    • California
      • San Francisco, California, 미국, 94158
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Victoria Wang
    • Connecticut
      • New Haven, Connecticut, 미국, 06510-3206
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Philippos Costa
    • Maryland
      • Bethesda, Maryland, 미국, 20817-1802
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Ralph Boccia
    • Missouri
      • Kansas City, Missouri, 미국, 64132
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Jaswinder Singh
    • Nebraska
      • Omaha, Nebraska, 미국, 68130-2042
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Kirsten Leu
    • New York
      • New York, New York, 미국, 10065
        • 모병
        • GSK Investigational Site
        • 수석 연구원:
          • Ciara Kelly
        • 연락하다:
        • 연락하다:
    • North Carolina
      • Durham, North Carolina, 미국, 27710
        • 모병
        • GSK Investigational Site
        • 수석 연구원:
          • Juneko Grilley-Olson
        • 연락하다:
        • 연락하다:
    • Ohio
      • Canton, Ohio, 미국, 44718
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Nashat Gabrail
    • Tennessee
      • Knoxville, Tennessee, 미국, 37920
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 수석 연구원:
          • Saikrishna Gadde
        • 연락하다:
    • Texas
      • Houston, Texas, 미국, 77030
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 수석 연구원:
          • Neeta Somaiah
        • 연락하다:
    • Washington
      • Seattle, Washington, 미국, 98109-4405
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Min Park
      • Barretos, 브라질, 14784-400
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Arinilda Bragagnoli
      • Florianópolis, 브라질, 88034-000
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Ana Paula Stramosk
      • Natal, 브라질, 59075-740
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Sulene Oliveira
      • Porto Alegre, 브라질, 90020-090
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Andreas Lutz
      • Vitória, 브라질, 29043-260
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • GLAUCIO BERTOLLO
    • Piauí
      • Teresina, Piauí, 브라질, 64002-530
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Welligton Figueiredo
      • Uppsala, 스웨덴, SE-751 85
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Sharmineh Moghaddam
      • Genolier, 스위스, 1272
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Michael Montemurro
      • BaracaldoVizcaya, 스페인, 48903
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Alberto Muñoz Llarena
      • Barcelona, 스페인, 8025
        • 모병
        • GSK Investigational Site
        • 수석 연구원:
          • Raul Teres Lleida
        • 연락하다:
        • 연락하다:
      • Madrid, 스페인, 28046
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Virginia Martinez Marin
      • Madrid, 스페인, 28034
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • María Ángeles Vaz Salgado
      • Madrid, 스페인, 28040
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Nadia Hindi Muñiz
      • Madrid, 스페인, 28041
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Aránzazu Manzano Fernández
      • Oviedo, 스페인, 33011
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Maria del Pilar Solis Hernandez
      • Seville, 스페인, 41013
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Irene Carrasco García
      • Valencia, 스페인, 46009
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Hector Augusto Aguilar Andino
      • Zaragoza, 스페인, 50009
        • 모병
        • GSK Investigational Site
        • 수석 연구원:
          • Javier Martínez Trufero
        • 연락하다:
        • 연락하다:
      • Buenos Aires, 아르헨티나, 1425
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Mariano Dioca
      • Capital Federal, 아르헨티나, C1426ANZ
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Yanina Pfluger
      • Ciudad Autonoma de Buenos Aire, 아르헨티나, C1414DRK
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Guillermo Mendez
      • Ciudad Autonoma de Buenos Aire, 아르헨티나, C1431FWO
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Julieta Grasselli
      • Ciudad autOnoma de Bueno, 아르헨티나, C1419AHN
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Samanta Straminsky
      • San Miguel de Tucumán, 아르헨티나, T4000IHE
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Ruben Segovia
      • London, 영국, SW3 6JJ
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Robin Jones
      • London, 영국, NW1 2PG
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Vasilios Karavasilis
      • Newcastle upon Tyne, 영국, NE7 7DN
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Anna Stansfeld
      • Sheffield, 영국, S10 2SJ
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Robin Young
    • Greater Manchester
      • Manchester, Greater Manchester, 영국, M20 4BX
        • 모병
        • GSK Investigational Site
        • 수석 연구원:
          • Alexander Lee
        • 연락하다:
        • 연락하다:
      • Milan, 이탈리아, 20133
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Elena Rosa Fumagalli
      • Milan, 이탈리아, 20141
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Roberta Giovanna Sanfilippo
      • Palermo, 이탈리아
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Giuseppe Badalamenti
      • Roma, 이탈리아, 00128
        • 모병
        • GSK Investigational Site
        • 수석 연구원:
          • Bruno Vincenzi
        • 연락하다:
        • 연락하다:
      • Ehime, 일본, 791-0280
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Tomohiro Nishina
      • Fukuoka, 일본, 812-8582
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Eiji Oki
      • Gifu, 일본, 501-1194
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Nobuhisa Matsuhashi
      • Hokkaido, 일본, 060-8648
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Yoshito Komatsu
      • Kanagawa, 일본, 241-8515
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Hiroki Osumi
      • Osaka, 일본, 565-0871
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Yukinori Kurokawa
      • Tokyo, 일본, 104-0045
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Hidekazu Hirano
      • Tokyo, 일본, 135-8550
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Masato Ozaka
      • Toyama, 일본, 930-0194
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Takayuki Ando
      • Yamaguchi, 일본, 755-8505
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Tatsuya Ioka
      • Beijing, 중국, 100141
        • 모병
        • GSK Investigational Site
        • 수석 연구원:
          • Jian Li
        • 연락하다:
        • 연락하다:
      • Chengdu, 중국, 610041
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Bo Zhang
      • Guangzhou, 중국, 510060
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Haibo Qiu
      • Guangzhou, 중국, 510655
        • 모병
        • GSK Investigational Site
        • 수석 연구원:
          • Yanhong Deng
        • 연락하다:
        • 연락하다:
      • Guangzhou, 중국, 510080
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Xinhua Zhang
      • Hangzhou, 중국, 310016
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Yu Zheng
      • Jinan, 중국, 250021
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Lei Cong
      • Nanjing, 중국
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Hao Xu
      • Shanghai, 중국, 200000
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Ye Zhou
      • Shanghai, 중국, 20001
        • 모병
        • GSK Investigational Site
        • 수석 연구원:
          • Ming Wang
        • 연락하다:
        • 연락하다:
      • Wuhan, 중국, 430022
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Kai-Xiong Tao
      • Zhengzhou, 중국, 450052
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Yang Fu
    • Ontario
      • Toronto, Ontario, 캐나다, M5G 2M9
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Albiruni Abdul Razak
    • Quebec
      • Montreal, Quebec, 캐나다, H3A 1A1
        • 모병
        • GSK Investigational Site
        • 수석 연구원:
          • Jonathan Noujaim
        • 연락하다:
        • 연락하다:
      • Warsaw, 폴란드, 02-781
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Piotr Rutkowski
      • Lyon, 프랑스, 69373
        • 모병
        • GSK Investigational Site
        • 수석 연구원:
          • Mehdi Brahmi
        • 연락하다:
        • 연락하다:
      • Reims, 프랑스, 51100
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Olivier Bouché
      • Helsinki, 핀란드, 00029
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Sari Jaamaa
    • Victoria
      • Melbourne, Victoria, 호주, 3004
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • John Zalcberg

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Is at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Informed consent form (ICF).

  • Has histologically or cytologically confirmed GIST that is metastatic and/or surgically unresectable.

  • Has not received prior systemic therapy for their metastatic and/or surgically unresectable GIST.

  • Tumor tissue must be provided to the central laboratory. Tumor tissues may be archival (preferred) or obtained from a fresh biopsy acquired for standard of care (biopsies must be collected before randomization).

  • Participants must have ≥1 target lesion (TL).

  • All participants must use adequate contraception according to local regulations throughout the study and for a specified period after the last dose of study medication (at least 30 days for velzatinib/imatinib, or 15 days for imatinib only, as applicable, or longer if local regulations specify).

  • Male participants must either be abstinent or use a male condom (with a recommendation for their female partner to use highly effective contraception). They must also refrain from donating semen.

  • Female participants must not be pregnant or breastfeeding.

    1. Those of non-childbearing potential are eligible without additional contraception.
    2. Those of childbearing potential must use an acceptable, highly effective contraceptive method and have a negative pregnancy test before starting the study. The investigator will assess their pregnancy risk.
  • Is capable of giving signed informed consent as described in the protocol, including compliance with the requirements and restrictions listed in the ICF and in this protocol.

  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.

  • Has adequate organ function.

Exclusion Criteria:

  • Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas [e.g., breast, cervix, bladder] that have been resected with no evidence of metastatic disease.

  • Has any clinically significant gastrointestinal abnormalities that may alter absorption, e.g., malabsorption syndrome or major resection of the stomach and/or bowels.

  • Has had any major surgery (minor surgical procedures such as central venous catheter placement and tumor needle biopsy are not considered major surgical procedures) within 14 days of the first dose of study treatment or participants who have not fully recovered from surgery.

  • Has any history of prior allogenic or autologous bone marrow transplant or other solid organ transplant. Participants with a history of autologous stem cell transplant are eligible for study participation provided the following eligibility criteria are met: a) transplant was [>100 days] prior to screening, and b) the participant has no active infection(s) at the time of screening.

  • Has known allergy or hypersensitivity to velzatinib or imatinib, in the opinion of the investigator or medical monitor, contraindicates participation in the study.

  • Has a history within 6 months prior of clinically significant or uncontrolled cardiac disease, unstable angina, acute myocardial infarction, New York Heart Association Class III or IV congestive heart failure [New York Heart Association,1994], or clinically significant arrhythmia not controlled by standard of care therapy, ventricular arrhythmia, cerebrovascular accident or transient ischemic attack and uncontrolled hypertension.

  • Has untreated brain or Central nervous system (CNS) metastases or brain/CNS metastases that have progressed [e.g., evidence of new or enlarging brain metastasis or new neurologic symptoms attributable to brain/CNS metastases]. Participants with previously treated and clinically stable brain/CNS metastases and who have completed all corticosteroid therapy for ≥2 weeks before randomization are not excluded from participation

  • Has ongoing adverse reaction(s) from prior therapy that has (have) not recovered to ≤Grade 1 or to the baseline status preceding prior therapy, (excluding e.g., alopecia, hearing loss, vitiligo, endocrinopathy managed with replacement therapy, and Grade 2 neuropathy) or that the investigator, with the agreement of the sponsor, considers to be not clinically relevant for the tolerability of study intervention in the current clinical study.

  • Has any active renal condition (e.g., infection, requirement for dialysis, or any other significant renal condition that could affect the participant's safety).

  • Has any serious and/or unstable medical or psychiatric disorder or other condition(s) (including laboratory assessment abnormalities) that could interfere with the participant's safety, obtainment of informed consent, or compliance to the study procedures.

  • Has received radiotherapy within 14 days prior to first dose of study treatment.

  • Has received any live vaccine within 30 days of randomization. Vaccination against Coronavirus disease 2019 (COVID-19) using vaccines that are authorized via the appropriate regulatory mechanisms (e.g., Emergency Use Authorization, Conditional Marketing Authorization, or Marketing Authorization Application) are not exclusionary.

  • Has received any transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including Granulocyte colony-stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 14 days before randomization.

  • Is currently enrolled or has participated in any other clinical study involving an investigational study intervention or any other type of medical research before signing ICF.

  • Has a positive drug/alcohol screening assessment.

  • Has a known Human immunodeficiency virus (HIV) infection and meets at least one of the following criteria:

    1. Has documented evidence of plasma HIV-1 ribonucleic acid (RNA) ≥50 c/mL within 3 months prior to or at screening. In the 3 to 12 months prior to screening, plasma HIV 1 RNA levels consistently <50 c/mL are required for enrollment; if multiple instances of plasma HIV-1 RNA values ≥50 c/mL occurred in the 3 to 12 months prior to screening, the participant is not eligible for enrollment unless, per the investigator's assessment, the elevations were neither persistent nor associated with antiretroviral resistance; OR
    2. Has not had CD4 cell counts measured in the past 12 months (i.e., at least two separate measurements taken a minimum of 28 days apart, one of which must be conducted at screening); OR
    3. Has had any CD4 cell count values ≤200 cells/mm3 in the past 12 months; OR
    4. Has had one or more changes in their combination antiretroviral therapy regimen (except for switches as allowed per details provided in protocol) or has received an antiretroviral therapy regimen that is inconsistent with locally recommended guidelines during the 3 months prior to screening; OR
    5. Has a history of HIV-associated non-Hodgkin lymphoma within 5 years prior to screening or a history of HIV-associated invasive cervical cancer; OR
    6. Has received treatment with an HIV 1 immunotherapeutic vaccine within 90 days of screening.
  • Is pregnant or breastfeeding.

  • Is unable to adhere to the protocol, including requirements for the Follow-up Period of the study.

  • Has an alanine aminotransferase (ALT) value >2.5x upper limit of normal (ULN) or (for participants with documented liver metastases/tumor infiltration) has an ALT value >5x ULN

  • Has a total bilirubin value >1.5x ULN.

  • Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice.

  • Evidence of chronic hepatitis B virus (HBV) infection with detectable viral load despite antiviral therapy with high resistance barrier.

  • 12-lead electrocardiogram (ECG) demonstrating mean QT interval corrected (QTc) corrected by Fridericia's formula >480msec at screening or history of long QT syndrome.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 이마티닙

Imatinib will be administered

다른 이름들:
  • GLIVEC / GLEEVEC
실험적: Velzatinib

Velzatinib will be administered

다른 이름들:
  • GSK6042981

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Progression-Free Survival (PFS) as assessed by Blinded independent central review (BICR)
기간: Up to approximately 74 months

PFS is defined as time from the date of randomization to the date of disease progression or death due to any cause, whichever occurs first.

Up to approximately 74 months

2차 결과 측정

결과 측정
측정값 설명
기간
Number of participants with Treatment-emergent adverse event (TEAEs) and serious adverse event (SAEs) by severity
기간: Up to approximately 75 months
Up to approximately 75 months
Number of participants with TEAEs/SAEs leading to dose reductions, interruptions and treatment discontinuation
기간: Up to approximately 75 months
Up to approximately 75 months
Number of participants with clinically significant changes in vital signs, electrocardiograms, and clinical laboratory parameters
기간: Up to approximately 75 months
Up to approximately 75 months
Plasma concentration of velzatinib
기간: Up to approximately 75 months
Up to approximately 75 months
Confirmed Objective Response Rate (ORR) as assessed by BICR
기간: Up to approximately 75 months

Confirmed ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) per response criteria.

Up to approximately 75 months
Overall survival (OS)
기간: Up to approximately 75 months

OS is defined as the time from the date of randomization to the date of death due to any cause.

Up to approximately 75 months
Confirmed ORR as assessed by Investigator assessment
기간: Up to approximately 75 months

Confirmed ORR is defined as the percentage of participants with a confirmed CR or PR per response criteria.

Up to approximately 75 months
Time from initial study randomization to second disease progression or death (PFS2)
기간: Up to approximately 75 months

PFS2 is defined as the time from initial study randomization to second disease progression or death after starting the next line of treatment.

Up to approximately 75 months
PFS as assessed by Investigator assessment
기간: Up to approximately 75 months

PFS is defined as time from the date of randomization to the date of disease progression or death due to any cause, whichever occurs first.

Up to approximately 75 months
Time to Response (TTR)
기간: Up to approximately 75 months

TTR as assessed by BICR and investigator, is defined as time from randomization until the first documented PR or CR that was subsequently confirmed.

Up to approximately 75 months
Duration of Response (DOR)
기간: Up to approximately 75 months

DOR as assessed by BICR and investigator, is defined as time from the first documented PR or CR that was subsequently confirmed until the first documented PD or death due to any cause.

Up to approximately 75 months
Time to Second Subsequent Therapy (TSST)
기간: Up to approximately 75 months

TSST is defined as the time from the date of randomization to the earliest date of second subsequent therapy or death due to any cause.

Up to approximately 75 months
Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) score
기간: Up to approximately 75 months

The EORTC QLQ-C30 includes 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies. These include functional scales, symptom scales, global health status scale, and single item scales. Scores are averaged and transformed to 0 to 100. Higher scores indicate greater functioning, better global health status, or more severe symptoms

Up to approximately 75 months
Time to confirmed deterioration (TTCD) of EORTC QLQ-C30
기간: Up to approximately 75 months

TTCD is defined as the time from the date of randomization to the first confirmed clinically meaningful deterioration on the Physical & Role Functioning & Global Health Status/QoL scales of the EORTC QLQ-C30.

Up to approximately 75 months
Number of participants with symptomatic AEs by severity as measured by patient-reported outcome Common Terminology Criteria for Adverse Events (PRO-CTCAE)
기간: Up to approximately 75 months

The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicities in participants in cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE.

Up to approximately 75 months
Number of participants with bothersome AEs/tolerability as measured by the Functional Assessment of Cancer Therapy - General (FACT-GP5)
기간: Up to approximately 75 months

The FACT GP5 is an assessment focused on the overall side effects impact to inform the tolerability of a treatment. The FACT GP5 ("I am bothered by side effects of treatment") responses are given on a 5-point Likert type scale. The response scale ranges from 0 (Not at all) to 4 (Very much). Higher scores indicate a higher degree of AE bother.

Up to approximately 75 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 7월 27일

기본 완료 (추정된)

2032년 8월 30일

연구 완료 (추정된)

2032년 9월 28일

연구 등록 날짜

최초 제출

2026년 5월 6일

QC 기준을 충족하는 최초 제출

2026년 5월 7일

처음 게시됨 (실제)

2026년 5월 13일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 23일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 22일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 306293
  • 2025-524934-24 (기타 식별자: EU CT Number)
  • 2025 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .